US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

ALDX Aldeyra Therapeutics Inc

3.86

-0.10 (-2.53%)

07 Jun 2024 - Cerrado

Retrasado por 15 minutos

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Aldeyra Therapeutics (NASDAQ:ALDX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Haga Click aquí para más Gráficas Aldeyra Therapeutics.

Aldeyra Therapeutics (NASDAQ:ALDX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024

Haga Click aquí para más Gráficas Aldeyra Therapeutics.

Noticias sobre Aldeyra Therapeutics Inc ALDX

Form 8-K - Current report
Viernes 7 de Junio 2024 (10 horas hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Jueves 6 de Junio 2024 (1 día hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Jueves 6 de Junio 2024 (1 día hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Jueves 6 de Junio 2024 (1 día hace) • Edgar (US Regulatory)

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
Miércoles 29 de Mayo 2024 (1 semana hace) • Business Wire

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
Miércoles 8 de Mayo 2024 (1 mes hace) • Business Wire

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
Jueves 25 de Abril 2024 (1 mes hace) • Business Wire

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
Jueves 18 de Abril 2024 (2 meses hace) • Business Wire

Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
Jueves 28 de Marzo 2024 (2 meses hace) • Business Wire

Form S-3 - Registration statement under Securities Act of 1933
Jueves 7 de Marzo 2024 (3 meses hace) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Jueves 7 de Marzo 2024 (3 meses hace) • Edgar (US Regulatory)

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Jueves 7 de Marzo 2024 (3 meses hace) • Edgar (US Regulatory)

Más de Aldeyra Therapeutics Inc Artículos de Noticias

Vontobel Financial Produ...

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones